CJC-1295 DAC 5mg

Description

OVERVIEW

CJC-1295 is a synthetic analogue of growth hormone-releasing hormone (GHRH) designed to increase plasma levels of growth hormone (GH) and insulin-like growth factor-1 (IGF-1). It is derived from the first 29 amino acids of GHRH, similar to Sermorelin and Modified GRF (1-29), but modified for enhanced stability and efficacy.

The DAC (Drug Affinity Complex) version of CJC-1295 includes an additional lysine linker, allowing it to bind to albumin, significantly extending its half-life. This prolonged activity leads to sustained GH release, reducing the need for frequent dosing compared to non-DAC versions.

Key Benefits of CJC-1295 DAC:

• Increases GH and IGF-1 levels
• Enhances protein synthesis and muscle recovery
• Boosts fat metabolism and supports weight management
• Improves sleep quality and cognitive function
• Preserves natural GH pulsatility, reducing side effects

RESEARCH

CJC-1295 and Growth Hormone Release

CJC-1295 binds to GHRH receptors, triggering GH secretion while maintaining the body’s natural pulsatile rhythm. Research findings indicate that:

• A single dose of CJC-1295 can increase GH levels by 2-10 times.
• Peak GH secretion occurs around 2 hours post-administration and remains elevated for 6-8 days.
• Unlike exogenous GH injections, which can suppress natural GH production, CJC-1295 stimulates endogenous GH release, minimizing suppression risks.

Comparison: CJC-1295 vs. CJC-1295 DAC

Feature	CJC-1295 (No DAC)	CJC-1295 DAC
Half-Life	~30 minutes	~8 days
Dosing Frequency	Multiple injections daily	Weekly
Mechanism	Short-acting GHRH analogue	Binds to albumin for sustained GH release

The DAC modification allows CJC-1295 to stay in circulation longer, preventing rapid degradation, and promoting longer-lasting GH stimulation.

Effects on Muscle Growth

Animal studies suggest that CJC-1295 enhances lean body mass through:

• Increased protein synthesis, supporting muscle hypertrophy and faster recovery.
• Improved nitrogen retention, aiding in muscle maintenance.
• Enhanced mitochondrial function, potentially boosting endurance and energy production.

CJC-1295 and Fat Metabolism

CJC-1295 has been linked to fat reduction and improved metabolic function by:

• Enhancing GH-induced fatty acid oxidation, leading to more efficient fat breakdown.
• Reducing fat accumulation, particularly visceral and subcutaneous fat.
• Improving insulin sensitivity, which helps regulate glucose levels and metabolic efficiency.

Clinical studies indicate significant fat loss in subjects using CJC-1295 over 12-24 weeks.

CJC-1295 and Sleep Quality

Research suggests that CJC-1295 may play a role in enhancing sleep cycles, particularly:

• Increasing deep (slow-wave) sleep, crucial for muscle repair, memory consolidation, and recovery.
• Modulating cortisol and stress hormones, leading to better relaxation and stress resilience.

These sleep-related benefits contribute to overall well-being, cognitive function, and physical recovery.

CJC-1295 and Anti-Aging Potential

Due to its ability to boost GH and IGF-1 levels, CJC-1295 has been explored for its potential in longevity and regenerative medicine. Benefits may include:

• Improved bone density, reducing age-related bone loss.
• Enhanced skin elasticity and collagen production, contributing to youthful skin.
• Cognitive protection, potentially aiding in neuroprotection and memory retention.

STRUCTURE

• Molecular Formula: C₁₅₂H₂₅₂N₄₄O₄₂
• Molecular Weight: 3647.954 g/mol
• Amino Acid Sequence: Tyr-D-Ala-Asp-Ala-Ile-Phe-Thr-Gln-Ser-Tyr-Arg-Lys-Val-Leu-Ala-Gln-Leu-Ser-Ala-Arg-Lys-Leu-Leu-Gln-Asp-Ile-Leu-Ser-Arg-Lys-DAC
• CAS Registry Number: 446262-90-4
• PubChem Identifier: 91976842

CITATIONS

1. Ionescu, M., & Frohman, L. A. Pulsatile secretion of growth hormone persists during continuous stimulation by CJC-1295. J. Clin. Endocrinol. Metab. (2006).
2. Alba, M. et al. Once-daily administration of CJC-1295, a long-acting GHRH analog, normalizes growth in knockout mice. Am. J. Physiol. Endocrinol. Metab. (2006).
3. Volpe, A. et al. Clinical use of growth hormone-releasing factor for induction of superovulation. Hum. Reprod. (1991).
4. Jetté, L. et al. hGRF1-29-Albumin Bioconjugates Activate the GRF Receptor on the Anterior Pituitary in Rats.Research Gate (2005).